The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid.This article was originally published on MedicalXpress.com
The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without diabetes. The findings were published in The Lancet […]
A recent multi-campus study, co-led by public health researchers from UC Irvine and UC Merced, published in the journal BMC Public Health is the first of its kind to examine California’s legislative approaches to prevent […]
So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you worry about how to handle gatherings where decadent food will […]
A team of researchers led by Pennington Biomedical Research Center’s Dr. Florina Corpodean has confirmed through a data analysis that metabolic and bariatric surgery is largely safe and effective for patients who are experiencing severe […]
Obesity has become a global epidemic, and the need for treatment and monitoring for people with obesity is growing. Researchers aiming to understand relevant biomarkers for the condition have fixed their gaze on leptin, a […]
A new study led by researchers at The University of Texas at Austin and Harvard Medical School reveals surprising findings about how babies exposed to gestational diabetes mellitus (GDM) grow during their first year of […]
Approximately 16% of the global population, or about 890 million people, suffer from obesity. The World Health Organization (WHO) has recognized obesity as a significant health issue and highlighted its impact on the quality of […]
Childhood obesity is a growing concern worldwide. But in New Zealand it’s a particularly pressing issue.This article was originally published on MedicalXpress.com
More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug semaglutide, a new analysis finds.This article was originally published on MedicalXpress.com
© 2025 SimplyWell.ca